


## CLAIMS

1. A compound having the formula (I):



5

wherein

X is selected from the radicals  $-\text{NR}_1-$  and  $-\text{CHR}_1-$ ;

Y is independently selected from O and S;

10 Z is independently selected from a  $\text{C}_{1-7}$  straight or  $\text{C}_{4-8}$  branched alkylene chain, a  $\text{C}_{2-7}$  alkenylene chain and a part of a  $\text{C}_{3-8}$  cycloalkyl or  $\text{C}_{5-8}$  cykloalkenyl ring structure;

Ar is an aryl group selected from aromatic carbocyclic ring systems, five- or six-membered heteroaromatic ring systems and bicyclic heteroaromatic ring systems;

$\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_3$  are independently selected from a group of substituents (a)-(d) consisting of:

- (a) H;
- 20 (b)  $\text{C}_{1-6}$  straight or  $\text{C}_{4-8}$  branched chain alkyl;
- (c)  $\text{C}_{3-8}$  cycloalkyl or  $\text{C}_{5-8}$  cykloalkenyl; and
- (d)  $\text{C}_{2-6}$  alkenyl or alkynyl;

wherein the substituents (b)-(d) optionally have at least one substituent independently selected from a group

25 (e)-(i) consisting of:

- (e) Ar, O-Ar or S-Ar;
- (f) OH, O-alkyl or S-alkyl, where alkyl is selected from the substituents (b)-(c);
- (g)  $\text{NR}_4\text{R}_5$ , where  $\text{R}_4$  and  $\text{R}_5$  are independently selected from the substituents (a)-(d) or optionally together form a nitrogen containing ring structure comprising from 2 to 5 carbon atoms;
- 30 (h)  $\text{NH}-\text{C}(\text{O})$ -alkyl,  $\text{C}(\text{O})$ -alkyl,  $\text{O}-\text{C}(\text{O})$ -alkyl or S-

C(O)-alkyl, where alkyl is selected from the substituents (b)-(c); and

(i) F, Cl or Br;

R<sub>6</sub> is selected from a group consisting of Ar and the substituents (a)-(c), where (b) and (c) are optionally substituted with at least one of the substituents (e)-(i); Ar optionally has at least one substituent independently selected from the substituents (b)-(i); and tautomers, solvates and pharmaceutically acceptable salts of said compound.

2. A compound according to claim 1, wherein X is a radical -NR<sub>1</sub>-.

3. A compound according to claim 2, wherein R<sub>1</sub> is H.

4. A compound according to any one of claims 1-3, wherein Y is O.

5. A compound according to any one of claims 1-4, wherein Ar is selected from phenyl and naphthyl.

6. A compound according to any one of claims 1-5, wherein Z is selected from -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>2</sub>-, -(CH<sub>2</sub>)<sub>3</sub>-, -(CH<sub>2</sub>)<sub>5</sub>-, -(CH<sub>2</sub>)<sub>6</sub>-, -(CH<sub>2</sub>)<sub>7</sub>- and *trans*-2-cyclohexylene.

7. A compound according to any one of claims 1-6, wherein R<sub>6</sub> is selected from isopropyl, cyclopentyl, cyclohexyl, phenyl, 4-*n*-butylphenyl, 4-isopropylphenyl and 2-naphthyl.

8. A compound according to any one of claims 1-7, wherein R<sub>2</sub> and R<sub>3</sub> are independently selected from H and 4-chlorobenzyl.

9. A compound according to any one of claims 1-8, wherein the compound is selected from a group consisting of:

4-[3-phenyl-1-(6-phenylhexyl)ureido]butyramide;

4-[1-(4-butylbenzyl)-3-phenylureido]butyramide;

4-[1-(4-isopropylbenzyl)-3-phenylureido]butyramide;

4-[1-(4-methylpentyl)-3-phenylureido]butyramide;

*N*-(4-chlorobenzyl)-4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide;

*trans*-2-[1-(3-cyclohexylpropyl)-3-phenylureido]cyclohexanecarboxamide;

4-[1-(3-cyclohexylpropyl)-3-naphthalen-2-yl-ureido]-butyramide;

5 4-[1-(2-naphthalen-2-yl-ethyl)-3-phenylureido]butyramide;

4-[1-(2-cyclohexylethyl)-3-phenylureido]butyramide;

4-(1-phenethyl-3-phenylureido)butyramide;

4-(1-benzyl-3-phenylureido)butyramide;

4-[1-(3-cyclopentylpropyl)-3-phenylureido]butyramide;

10 4-[3-phenyl-1-(5-phenylpentyl)ureido]butyramide; and

4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide.

10. A compound according to claim 1, wherein X is a radical -CHR<sub>1</sub>-.

11. A compound according to claim 10, wherein said  
15 radical -CHR<sub>1</sub>- is selected from -CH<sub>2</sub>- and (R)-CH(CH<sub>3</sub>)-.

12. A compound according to any one of claims 10-11, wherein Y, Z, Ar, R<sub>2</sub>, R<sub>3</sub> and R<sub>6</sub> are as defined in claims 4-8.

13. A compound according to any one of claims 10-12,  
20 wherein the compound is selected from a group consisting of:

(R)-4-[(3-cyclohexylpropyl)-(2-phenylpropionyl)amino]-butyramide;

25 4-[(3-cyclohexylpropyl)-(2-naphthalen-2-yl-acetyl)amino]-butyramide; and

8-[(3-cyclohexylpropyl)-(2-naphthalen-2-yl-acetyl)amino]-octanamide.

14. A compound according to any one of claims 1-13 for use as a pharmaceutical.

30 15. A pharmaceutical composition comprising a compound according to any one of claims 1-13 as active ingredient in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

16. Use of a compound according to any one of claims  
35 1-13 for the manufacture of a medicament for treatment of pain and disorders related thereto.

17. A method for treatment of pain and disorders related thereto, wherein said method comprises administering to an animal, including human, patient of a therapeutically effective amount of a compound according to any  
5 one of claims 1-13.